Ebola Outbreak in DRC and Uganda: May 2026 Status Report
On May 17, 2026, the World Health Organization declared the Ebola outbreak spreading through the Democratic Republic of the Congo and Uganda a Public Health Emergency of International Concern (PHEIC) — the highest level of alert the global health body can issue. The outbreak, caused by the rare Bundibugyo species of Ebola virus, has outpaced containment efforts and is now described by the WHO as characterized by “alarming scale and speed.” As of late May, the situation continues to deteriorate despite an intensive international response.
Timeline and Scale
The outbreak was first detected on May 5, 2026, when the WHO was alerted to a high-mortality outbreak of unknown illness in the Mongbwalu Health Zone of Ituri Province, DRC. Laboratory confirmation of Ebola disease came on May 15, and the identification of the Bundibugyo ebolavirus species — a rarer variant previously documented in only two outbreaks, in 2007 and 2012 — raised immediate concerns about limited experience with this particular strain’s behavior and transmission dynamics.
By May 26, the DRC Ministry of Health reported 121 confirmed cases (including 17 deaths) and 1,077 suspected cases. UN News reports indicate more than 900 suspected cases and 220 suspected deaths across the affected region. The significant gap between confirmed and suspected cases reflects the challenges of laboratory testing in a region with limited infrastructure and security constraints. The case fatality rate among confirmed cases stands at approximately 14%, though this figure may evolve as more outcomes are documented.
The outbreak has spread beyond the DRC’s borders into neighboring Uganda, raising the specter of a multi-country epidemic that would be significantly harder to contain. Cross-border movement in the region is substantial, and the densely populated areas of eastern DRC and western Uganda create conditions conducive to sustained transmission.
The Bundibugyo Strain: A Known Unknown
The Bundibugyo ebolavirus species was first identified during an outbreak in Uganda’s Bundibugyo District in 2007, which resulted in 149 cases and 37 deaths. A second outbreak occurred in the DRC’s Orientale Province (now part of Ituri) in 2012, with 77 cases and 36 deaths. Unlike the Zaire ebolavirus species responsible for the devastating 2014-2016 West African epidemic — for which vaccines and therapeutic monoclonal antibodies have been developed — Bundibugyo virus has no licensed vaccine and no proven specific treatment.
This therapeutic gap is critically important. The Ervebo vaccine, which proved highly effective against the Zaire strain during the 2018-2020 DRC outbreak, does not protect against Bundibugyo virus. Experimental vaccine candidates exist but have not been tested in outbreak settings, and manufacturing sufficient doses for a mass vaccination campaign would take months even under emergency authorization. The WHO and partners are evaluating whether candidate vaccines can be deployed under compassionate use protocols, but the timeline for meaningful vaccine availability remains uncertain.
Containment Challenges
The outbreak zone presents formidable obstacles to containment. Ituri Province has been plagued by armed conflict for decades, with dozens of militia groups operating in areas that overlap with the outbreak’s epicenter. Health workers require armed escorts to reach affected communities, and security incidents have repeatedly interrupted contact tracing and vaccination campaigns in previous DRC Ebola outbreaks. The UN has warned that the epidemic is “spreading rapidly and outpacing containment efforts.”
Healthcare infrastructure in the region is fragile. The General Referral Hospital of Mongbwalu — the primary treatment facility for the outbreak — has limited isolation capacity, inconsistent electricity, and shortages of essential supplies including personal protective equipment. Health workers have been among the cases, a pattern seen in previous Ebola outbreaks that both reduces the available workforce and amplifies community fear of health facilities.
Community mistrust, a recurring challenge in Ebola responses, is compounded by the unfamiliarity of Bundibugyo virus. Communities that have experienced previous Zaire ebolavirus outbreaks may not recognize Bundibugyo disease as Ebola, and the lack of a familiar vaccine as a response tool removes one of the most effective trust-building interventions used in recent outbreaks. Safe and dignified burial practices, essential for interrupting transmission chains, require community cooperation that cannot be assumed in this context.
International Response
The WHO’s PHEIC declaration has triggered accelerated international mobilization. The CDC issued a Health Alert Network advisory on May 15, alerting U.S. clinicians and public health agencies to the outbreak and providing guidance on case identification and infection control. The European Centre for Disease Prevention and Control (ECDC) is monitoring the situation and has published risk assessments. ReliefWeb is coordinating humanitarian response documentation, and multiple NGOs — including Médecins Sans Frontières, the International Rescue Committee, and the Red Cross — have deployed teams to the region.
However, the international response faces headwinds. The restructuring of U.S. federal health agencies under the Trump administration, including significant cuts to CDC’s global disease detection capacity, has raised concerns about America’s ability to contribute at the level of previous Ebola responses. The CDC’s reduced workforce and reorganized structure come at precisely the moment when experienced epidemiologists and logisticians are most urgently needed.
The IRC’s 2026 Emergency Watchlist ranked the DRC seventh among countries most at risk of worsened humanitarian crisis — and that ranking predated the current outbreak. The compound challenges of ongoing conflict, food insecurity, displacement, and now a PHEIC-level Ebola outbreak create a humanitarian scenario of exceptional complexity.
What Comes Next
The trajectory of this outbreak depends on several factors: the speed with which candidate vaccines can be deployed (if at all), the effectiveness of contact tracing in insecure areas, community acceptance of public health measures, and the adequacy of international funding. The WHO has called an urgent meeting on the crisis, and donor pledges are being solicited.
For the global health community, the Bundibugyo outbreak is a stark reminder that the Ebola threat has not receded — it has diversified. The existence of at least four distinct ebolavirus species capable of causing human disease (Zaire, Sudan, Bundibugyo, and Taï Forest) means that preparedness must encompass a broader range of pathogens than the post-2014 focus on Zaire ebolavirus addressed. Developing vaccines and therapeutics for all medically important filoviruses — not just the one that caused the largest epidemic — must be a global priority.
As of late May 2026, the situation remains fluid. Case counts continue to rise, containment measures are being scaled up, and the international community is mobilizing — but the gap between the pace of the outbreak and the pace of the response remains the defining feature of this emergency.
